Michael Martin Breen - 16 Feb 2021 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Role: Director
Signature: /s/ Michael Martin Bree
Issuer symbol: GTBP
Transactions as of: 16 Feb 2021
Net transactions value: +$170,347
Form type: 4
Filing time: 12 Nov 2021, 11:01:45 UTC
Previous filing: 12 Nov 2021
Next filing: 19 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GTBP	Common Stock	Award	$0	+278,058		$0.000000	278,058	16 Feb 2021	Direct	F1
transaction	GTBP	Common Stock	Conversion of derivative security	$136,826	+40,243	+14%	$3.40^*	318,301	25 Feb 2021	Direct
transaction	GTBP	Common Stock	Conversion of derivative security	$33,521	+9,859	+3.1%	$3.40^*	328,160	25 Feb 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GTBP	Option to purchase Common Stock	Award	$0	+50,000		$0.000000	50,000	16 Feb 2021	Common Stock	50,000	$6.33	Direct	F2
transaction	GTBP	10% Senior Convertible Debenture	Conversion of derivative security	$0	-100,000	-100%	$0.000000^*	0	25 Feb 2021	Common Stock	40,243	$3.40	Direct	F3
transaction	GTBP	10% Senior Convertible Debenture	Conversion of derivative security	$0	-30,000	-100%	$0.000000^*	0	25 Feb 2021	Common Stock	9,859	$3.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on January 13, 2021, 2022 and 2023.
F2	1/3rd of the shares vest on February 16, 2021, 2022 and 2023.
F3	While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding until converted.